Apnimed scouts $160m IPO to back late-stage sleep apnoea pill development

Apnimed is eyeing a spot connected the Nasdaq speech done an IPO worthy up to $160m, which volition enactment the institution arsenic it looks to debut its perchance "best-in-class" therapy connected the US obstructive slumber apnoea (OSA) market.

Through its nationalist marketplace launch, which volition spot the Massachusetts-based biotech commercialized nether the ticker 'APMD', Apnimed volition connection retired 10,000,000 of its shares astatine betwixt $14 and $16 per portion to prospective buyers, taking the imaginable full of this rise up to $160m. This sum could emergence further, however, arsenic Apnimed plans to connection 1,500,000 further shares – perchance allowing the institution to slope a further $24m depending connected underwriter interest.

With the IPO funds, Apnimed plans to chiefly dedicate the currency to taking its pb candidate, oxnimbi, to the OSA marketplace – dedicating astir $228.8m from the IPO and existing funds to enactment the regulatory process and the imaginable commercialisation of the drug. On apical of its efforts to commercialise oxnimbi, Apnimed plans to usage immoderate of the remaining currency from the IPO to money its R&D activities for further cause candidates.

The biotech designed oxnimbi, different known arsenic AD109, to heighten musculus enactment successful the precocious airways to forestall airway illness during sleep. The cause is presently nether reappraisal by the US Food and Drug Administration (FDA) for imaginable support successful OSA, with the regulator readying to marque a telephone connected oxnimbi earlier 28 February 2027 based connected affirmative information Apnimed has filed from the drug's Phase III programme successful the condition.

Addressing unmet needs successful OSA

While aggregate device-based attraction options are disposable to patients for OSA, a notable information of those with the information either ineligible oregon unwilling to usage a continuous affirmative airway unit (CPAP) machine, which enactment by keeping the airways unfastened during sleep.

If the FDA were to greenlight oxnimbi, the cause would go the archetypal oral therapy to scope the OSA market, which mostly remained stagnant until 2024, erstwhile Eli Lilly's blockbuster value nonaccomplishment drug, Zepbound (tirzepatide), became the archetypal pharmaceutical to unafraid support successful OSA.

Zepbound's support offered obese patients the archetypal caller attraction enactment for this condition. However, arsenic per a 2024 reappraisal published successful Sleep Medicine. lone conscionable implicit a 3rd of patients with OSA are considered clinically obese, meaning galore patients are not eligible for Zepbound successful this context.

By debuting a attraction suitable for each types of OSA, careless of a patient's weight, Apnimed hopes oxnimbi volition go the best-in-class attraction for the condition, which presently impacts 936 cardinal individuals worldwide.